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ARTICLE
Propionic and Methylmalonic Acidemia: Antisense Therapeutics
for Intronic Variations Causing Aberrantly Spliced Messenger RNA
A. Rinco´n,* C. Aguado,* L. R. Desviat, R. Sa´nchez-Alcudia, M. Ugarte, and B. Pe´rez
We describe the use of antisense morpholino oligonucleotides (AMOs) to restore normal splicing caused by intronic
molecular defects identified in methylmalonic acidemia (MMA) and propionic acidemia (PA). The three new point
mutations described in deep intronic regions increase the splicing scores of pseudoexons or generate consensus binding
motifs for splicing factors, such as SRp40, which favor the intronic inclusions in MUT (r.1957ins76), PCCA (r.1284ins84),
or PCCB (r.654ins72) messenger RNAs (mRNAs). Experimental confirmation that these changes are pathogenic and cause
the activation of the pseudoexons was obtained by use of minigenes. AMOs were targeted to the 5′ or 3′ cryptic splice
sites to block access of the splicing machinery to the pseudoexonic regions in the pre-mRNA. Using this antisense
therapeutics, we have obtained correctly spliced mRNA that was effectively translated, and propionyl coenzyme A (CoA)
carboxylase (PCC) or methylmalonylCoA mutase (MCM) activities were rescued in patients’ fibroblasts. The effect of
AMOs was sequence and dose dependent. In the affected patient with MUT mutation, close to 100% of MCM activity,
measured by incorporation of 14C-propionate, was obtained after 48 h, and correctly spliced MUT mRNA was still detected
15 d after treatment. In the PCCA-mutated and PCCB-mutated cell lines, 100% of PCC activity was measured after 72 h
of AMO delivery, and the presence of biotinylated PCCA protein was detected by western blot in treated PCCA-deficient
cells. Our results demonstrate that the aberrant inclusions of the intronic sequences are disease-causing mutations in
these patients. These findings provide a new therapeutic strategy in these genetic disorders, potentially applicable to a
large number of cases with deep intronic changes that, at the moment, remain undetected by standard mutation-detection
techniques.
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In the past few years, special attention has been given in
the field of genetic diseases to research on mutations af-
fecting splicing, which generally account for 10%–30% of
the total mutant alleles1 and for which novel pharmaco-
logical and molecular therapies have begun to be tested.2
Most of the mutations affecting splicing disrupt conserved
sequences at the exon-intron junctions—namely, the 5′
donor site, the 3′ acceptor site, the polypyrimidine tract
and the branch-point sequence—with different conse-
quences (exon skipping, activation of cryptic splice sites,
etc.) depending on the local sequence context.3–5 Some
mutations affect less well-conserved auxiliary splicing se-
quences—that is, exonic and intronic splicing enhancers
or silencers—which are recognized by specific SR pro-
teins.6 Other types of mutations, rather than disrupting
conserved splice sites, create novel ones that are errone-
ously used by the splicing machinery, resulting in the gen-
eration of aberrant transcripts.4,5 These mutant-activated
splice sequences generally occur deep in introns, causing
the abnormal inclusion of intron sequences (pseudoex-
ons) in the mRNA.7,8 The true prevalence of this type of
mutations is probably underestimated because few labo-
ratories analyze intron sequences far from coding regions,
and, in cDNA, the corresponding transcripts (usually with
a frameshift and a premature termination codon [PTC])
are degraded by the nonsense-mediated mRNA decay
(NMD) mechanism. NMD is a well-conserved mechanism
that occurs naturally in cells and that actively degrades
PTC-bearing transcripts, thus preventing the generation
of truncated proteins that are potentially toxic to cells.9
Alleles with intronic mutations activating cryptic splice
sites are particularly amenable to therapeutic correction
if use of the aberrant splice sites can be blocked, because
the wild-type splice sites remain intact, thus retaining the
potential for normal splicing. In this respect, antisense
oligonucleotides have been used successfully to restore
normal splicing in several disease models, such as b-thal-
assemia/HbE disorder,10 cystic fibrosis,11 ocular albinism
type I,8 and ataxia telangiectasia.12 Antisense oligonucle-
otides modulate the splicing pattern by steric hindrance
of the recognition and binding of the splicing apparatus
to the selected cryptic sequences, thus forcing the ma-
chinery to use the natural sites. This strategy has also been
used in Duchenne muscular dystrophy to force the skip-
ping of a deleterious exon containing a premature stop
codon.13
In this work, we report the identification of three novel
deep intronic mutations that lead to the insertion of a
pseudoexon or cryptic exon in the mRNA of patients with
methylmalonic acidemia (MMA [MIM 251000]) or pro-
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pionic acidemia (PA [MIM 606054]). These are the two
most frequent organic acidemias affecting the propionate
oxidation pathway in the catabolism of several amino ac-
ids, odd-chain fatty acids, and cholesterol.14 Both are life-
threatening diseases that appear in the neonatal or infan-
tile period and are caused by different gene defects
inherited in autosomal recessive fashion and affecting the
synthesis or function of two of the major enzymes of the
pathway, propionyl coenzyme A (CoA) carboxylase (PCC
[EC 6.4.1.3]) and methylmalonylCoA mutase (MCM [EC
5.4.99.2]), or of their coenzymes (biotin and adenosyl-
cobalamin, respectively). Three consecutive enzymatic re-
actions are responsible for the conversion of proponylCoA
to the succinylCoA that enters the Krebs cycle. The first
reaction involves PCC that catalyzes the carboxylation of
propionylCoA to D-methylmalonylCoA, which is then
converted to the L form by a racemase, and, finally, the
MCM enzyme catalyzes the isomerization of L-methyl-
malonylCoA to succinylCoA.14
Mutations in any of the two genes, PCCA or PCCB,
which encode both subunits of the PCC enzyme, cause
PA, whereas mutations in the MUT gene, which encodes
the MCM enzyme, or in the genes MMAA and MMAB (re-
sponsible for the intramitochondrial synthesis of adeno-
sylcobalamin) cause isolated MMA. The molecular bases
of these disorders are well known, with 150 different mu-
tations described for each of the PCCA, PCCB, and MUT
genes. Missense mutations are the most frequent defects,
followed by splicing mutations, which account for 15%–
20% of the total alleles.15,16
In this work, we describe three genomic alterations—
one in the MUT gene, one in the PCCA gene, and one in
the PCCB gene—that are responsible for the aberrant in-
sertion of intronic sequences in patients’ mRNA. The in-
tronic pseudoexons aberrantly inserted in the mRNA were
targeted with antisense morpholino oligonucleotides
(AMOs) that prevent aberrant splicing, thus generating
normal mRNA, which is translated into functional pro-
tein, achieving therapeutic correction of the defect.
Material and Methods
Genetic Analysis of Fibroblast Cell Lines
The study included fibroblast cell lines from one Spanish patient
with MMA described elsewhere17 and from two patients from
Turkey with PA, one PCCA deficient and the other PCCB deficient.
Genetic analysis was performed using fibroblast cell lines as the
source of mRNA and genomic DNA (gDNA). Total mRNA was
isolated by Tripure Isolation reagent (Roche), and subsequent RT-
PCR was done using primers and conditions described else-
where.17,18 The PCR products were sequenced with the same prim-
ers used for amplification, with BigDye Terminator v.3.1 mix and
subsequent analysis by capillary electrophoresis on an ABI Prism
3700 Genetic Analyzer (Applied Biosystems). BLAST analysis was
used to localize the inserted sequence. Intronic gDNA was am-
plified using primers located in intron 14 (5′-GTAACCCGTTTAC-
TAGTTGCC-3′ and 5′-CACTATAACATACCTGAAGGG-3′) for the
PCCA gene insertion, primers located in intron 5 (5′-TATCTTTCC-
ACAGATAATGCCTC-3′) and intron 6 (5′-AAGCAAGGTTTGAGA-
TGAATGG-3′) for the PCCB gene insertion, and primers located
in intron 11 (5′-GGCTTCCAGCTTCATCCATG-3′ and 5′-TGGCAC-
GTGCCTGTAGTACC-3′) for the MUT gene insertion. The inser-
tions and gDNA mutations were described as recommended by
the Human Genome Variation Society (HGVS). The DNA muta-
tions are numbered on the basis of cDNA sequence and intronic
positions described in Ensembl. The genomic changes were stud-
ied in 300 control alleles by restriction analysis with use of NlaIII,
BsaAI, and BbsI to detect the PCCA, PCCB, and MUT intronic
mutations, respectively.
Splice scores of the natural and cryptic donor and acceptor sites
were determined using the analysis tools from the Berkeley Dro-
sophila Genome Project (BDGP), and prediction of the presence
of exonic splice enhancer or silencer sequences was performed
using ESEfinder,6 Rescue-ESE19 (RESCUE-ESE Web Server), and
PESX20 (PESXs Server).
Oligonucleotide Treatment and Analysis
The 25-mer AMOs were designed, synthesized, and purified by
Gene Tools and were targeted to donor or acceptor cryptic splice
sites in the pre-mRNA for each of the intronic inserted sequences
in accordance with the manufacturer’s criteria.21 The sequence of
the AMOs used is shown in figure 1. Endo-Porter (Gene Tools)
was used as the delivery mechanism. For AMO treatment,
fibroblast cells were grown in 6-well plates, and, after54–5# 10
overnight culture, different concentrations of AMO with 6-8 ml/
ml of Endo Porter were added to the culture medium. Cells were
harvested at different times, and mRNA was isolated as described
above.
As we have described elsewhere,17 the affected patient with an
MUT mutation is compound heterozygous for the intronic in-
sertion and a splicing mutation in the last nucleotide of exon 10
(c.1808GrA), which produces two aberrant transcripts as a result
of the use of cryptic splice sites. For RT-PCR in this patient, we
used a forward primer placed at the junction of exons 10 and 11
(5′-GCTATCAAGAGGGTTCATAAATT-3′) and a reverse primer lo-
cated in exon 13 (5′-CTTAGAAGAAGAGATTTT-3′) to amplify only
the allele corresponding to the pseudoexon insertion between
exons 11 and 12. In some cases, a forward primer placed at the
junction of exon 11 and inserted intronic sequence (5′-TCTTTTC-
CAGAGTCTCGCTCTTT-3′) was used to selectively amplify the
cDNA containing the intronic insertion. For RT-PCR analysis of
PCCA- and PCCB-deficient cell lines, we used primers described
elsewhere.18
PCC activity was assayed as described elsewhere,22 and 14C pro-
pionate incorporation into acid-precipitable material was deter-
mined in intact cells grown in basal medium as propionate me-
tabolism via MCM.23 For the detection of biotin-bound proteins,
fibroblasts were harvested by trypsinization and were freeze
thawed, and protein concentration in cell extracts was deter-
mined by the Bradford assay. Equal amounts of total protein (30–
50 mg) from each sample were loaded onto a denaturing 6% poly-
acrylamide gel. After electrophoresis, proteins were transferred to
PVDF membranes (Immobilon-P [Millipore]), and the biotin-con-
taining proteins were detected with an avidin alkaline phospha-
tase conjugate as described elsewhere.24
Minigene Construction and in Vitro Splicing Analysis
For evaluation of in vitro splicing, the pSPL3 vector (Life Tech-
nologies [Gibco BRL], kindly provided by Dr. B. Andresen) was
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Figure 1. Schematic representation of MUT, PCCA, and PCCB regions around the pseudoexons. Exons and pseudoexons are boxed. The
inserted intronic sequence is shown in uppercase letters, and the surrounding intronic sequence is in lowercase letters. The sequence
of the AMO used is underlined, and splice scores calculated with the BDGP software are denoted above the corresponding 5′ and 3′
splice sites. The mutations are denoted by arrows.
used. Gene fragments corresponding to each pseudoexon and
flanking regions were amplified from patients and from control
DNA and were cloned into the TOPO vector (Invitrogen). For the
PCCB minigene, the amplified fragment included exon 6. The
insert was excised with EcoRI and subsequently was cloned into
pSPL3. Clones containing the desired normal and mutant inserts
in the correct orientation were identified by restriction-enzyme
analysis and automated DNA sequencing. Samples of 2 mg of the
wild-type or mutant minigenes were transfected into Hep3B cells
by use of Jetpei (Polyplus transfections), in accordance with the
manufacturer’s recommendations. At 24–48 h after transfection,
cells were harvested, RNA was purified, and RT-PCR analysis was
performed using the pSPL3-specific primers SD6 and SA2 (Exon
Trapping System [Gibco BRL]). Amplified products were separated
by agarose gel electrophoresis and were further analyzed by ex-
cising the bands from the gel by means of the Qiaex Gel extrac-
tion kit (Qiagen) and subsequent direct sequencing.
Results
Genetic Analysis of Patients
The three patients with MMA and PA exhibited aberrantly
spliced mRNA with an amplified band that was larger than
normal after RT-PCR analysis. Direct sequencing of the
products obtained by RT-PCR and subsequent BLAST
search revealed that the insertions corresponded to in-
tronic sequences flanked by cryptic 5′ and 3′ splice sites,
thus resembling a pseudoexon (fig. 1). In all three patients
the presence of intronic mutations presumably activates
the pseudoexon (table 1), whereas the naturally used ad-
jacent splice sites of the surrounding exons remain func-
tional (fig. 1). These intronic variants were not present in
the National Center for Biotechnology (NCBI) dbSNP, and
none were found in 300 control alleles analyzed.
In the MUT-deficient affected patient, we had previously
detected a 76-bp insertion between exons 11 and 12
(r.1957ins76) in the heterozygous state and corresponding
to an exon-like region in intron 11.17 In controls and pa-
tients with other mutations, the insertion transcript could
be detected using a specific primer.17 The patient’s DNA
was found to have a new CrA change in intron 11 at
position 7 relative to the inserted sequence (IVS11-
891CrA) (fig. 1). The scores of the 5′ and 3′ cryptic splice
sites were 0.72 and 0.98, respectively, and the CrA mu-
tation increased the 5′ cryptic splice site to 0.99. Addi-
tional in silico analysis revealed no significant changes in
splicing regulatory sequences caused by the mutation (no
exonic splicing enhancer [ESE] or exonic splicing sup-
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Figure 2. Splicing assay for the wild-type and mutant minigenes
corresponding to the MUT (A), PCCA (B), and PCCB (C) intronic
changes. The results of the RT-PCR analysis using vector-specific
primers are shown along with the schematic representation of the
transcripts obtained, which were characterized by sequence anal-
ysis. V p vector exonic sequences. The solid line in panel C cor-
responds to a cryptic exon generated during the cloning process.
Table 1. Inserted Intronic Sequences, Genomic Intronic Variations, and in Silico Analysis of Genomic Change
Gene (IDa)
Origin of
Inserted
Sequence mRNA Changeb gDNA Changeb In Silico Effect of gDNA Changec
MUT (4594) Intron 11 r.1957ins76 CrA in position 7 of 5′ donor site
of pseudoexon (IVS11-891CrA)
Increase in splicing score (from .98 to .99)
PCCA (5095) Intron 14 r.1284ins84 ArG in the middle of pseudoexon
(IVS14-1416ArG)
Creates SRp40 binding site and eliminates SRp55
binding site
PCCB (5096) Intron 6 r.654ins72 ArG in position 5 of 5′ donor site
of pseudoexon (IVS6462ArG)
Increase in splicing score (from .93 to 1) in 5′ donor
site of pseudoexon
a Gene identification (ID) numbers correspond to the NCBI Entrez Gene database.
b Mutation nomenclature is as recommended by HGVS. GenBank accession numbers NT_007592 (MUT), NM_000282.2 (PCCA), and NM_000532.3
(PCCB) were used. The genomic and transcript sequences were obtained using Ensembl.
c In silico effect analyzed by ESEfinder and BDGP.
pressor [ESS] predicted by Rescue-ESE and PESX programs
and just a slight decrease in the scores for SC35, SRp40,
and SRp55 by ESEfinder analysis).
In the PCCA-deficient affected patient, we have iden-
tified an 84-bp insertion between exons 14 and 15 of the
PCCA gene (r.1284ins84) in a homozygous state. This 84-
bp insertion corresponds to a pseudoexon in intron 14
and is readily detected in patients with mRNA-destabiliz-
ing mutations and even at low levels in control cell lines25
but never in a homozygous state. No other sequence
changes were detected in the amplified cDNA from the
patient. The pseudoexon was amplified from gDNA of the
patient and was sequenced, revealing an ArG substitution
(IVS14-1416ArG) in the middle of the inserted sequence.
In silico analysis with ESEfinder prediction software
showed that the change created an SRp40 binding site and
eliminated an SRp55 binding site. Rescue-ESE predicted
loss of an ESE sequence and creation of two novel ones.
No change was predicted by the PESX program.
In the PCCB-deficient affected patient, we have iden-
tified a new 72-bp insertion between exons 6 and 7 in the
PCCB gene (r.654ins72) in a homozygous state, corre-
sponding to an intron 6 region resembling an exon with
3′ and 5′ splice sites with high scores (fig. 1). Direct se-
quencing of the genomic region identified an ArG sub-
stitution at position 5 relative to the inserted sequence
(IVS6462ArG), increasing the cryptic 5′ donor splic-
ing score from 0.93 to 1. Additional in silico analysis pre-
dicted creation of an SRp55 site (ESEfinder) and elimi-
nation of a putative silencer (PESX). Rescue-ESE predicted
no changes.
Functional Analysis of the Intronic Changes
To provide evidence that the observed intronic changes
are the cause of the pseudoexon inclusion in the patients’
mRNA, the splicing pattern associated with these changes
was further evaluated using minigenes. Minigene con-
structs with wild-type and mutant pseudoexons and flank-
ing sequences were generated in the pSPL3 vector. The
results of splicing analysis after transfection in Hep3B cells
are shown in figure 2. The wild-type PCCA and PCCB mini-
gene constructs showed practically total absence of pseu-
doexon inclusion. The MUT wild-type minigene produced
two bands corresponding to the pseudoexon insertion and
to a splicing event between the vector splice sites. The
mutant constructs resulted in the pseudoexon inclusion
in all cases, representing the major transcript for the MUT
and PCCB minigenes and part of the transcripts for the
PCCA minigene. Sequence analysis confirmed the identity
of the transcripts in all cases. The major transcript ob-
tained from the PCCB mutant minigene corresponds to
the pseudoexon inclusion along with the insertion of a
vector sequence caused by the cloning-derived creation of
a 3′ splice acceptor site, which was chosen along with a
cryptic 5′ splice site present in the vector (Exon Trapping
System [Life Technologies]).
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Figure 3. Correction of aberrant splicing of MUT, PCCA, and PCCB
genes by AMO targeted to the pseudoexon 5′ or 3′ splice sites. A,
RT-PCR analysis of the MUT-mutated cell line of total RNA extracted
from untreated cells (0 mM) and treated for different times with
the specified amounts of AMO targeted to the 5′ cryptic splice site.
The sense primer used is located at the junction of exons 10 and
11, and the reverse primer is located in exon 13. B, RT-PCR analysis
of the PCCA-deficient cell line untreated or treated for 72 h with
10 or 20 mM of the corresponding AMO targeted to the 3′ splice
site. C, RT-PCR analysis of the PCCB-deficient cell line untreated
or treated for 72 h with 10 or 20 mM of AMO targeted to the 5′
splice site. Lane C, Control cell line.
Restoration of Correct Splicing in MUT-, PCCA-,
and PCCB-Mutated Fibroblast Cell Lines
To demonstrate that these changes are disease-causing
mutations in the patients and to try to rescue PCCA, PCCB,
and MUT expression in the patients’ fibroblasts, we have
investigated the possibility of redirecting transcript pro-
cessing by modified AMOs. The AMOs used were com-
plementary to the 5′ or 3′ cryptic splice sites of the intronic
sequences inserted (fig. 1), to block access of the splicing
machinery to the pre-mRNA. In all three cases, RT-PCR
analysis demonstrated that the AMO used abolished the
alternatively spliced transcript induced by the mutations
(fig. 3).
The optimal conditions for AMO treatments were de-
termined in each fibroblast cell line. The exclusion of in-
tronic sequences in all cases was oligonucleotide se-
quence–specific, since AMO targeted to another gene had
no effect on pseudoexon inclusion (data not shown). In
untreated cell lines, practically no correctly spliced mRNA
was detected, as shown by the lack of band comigrating
with that of the control one (fig. 3). The correctly spliced
fragment was generated 24 h after treatment of the cell
lines with AMO complexed with peptide carrier. The prod-
ucts of aberrant splicing were either absent or present at
much lower levels (fig. 3). The identity of the PCR products
was always confirmed by sequencing.
In the MUT-mutated fibroblast cell line, AMO targeted
to the 5′ splice site prevented the inclusion of the intronic
sequence 24 h after treatment. The experiments showed
dose-dependent correction of splicing (fig. 3A). The larger
band containing the intronic insertion was detected with
10 mM AMO but not with 15 and 20 mM AMO. Using a
primer located in the junction of exon 11 and the inserted
pseudoexon to rescue the larger band, we observed essen-
tially the same results (data not shown).
To test the stability of the restored, correctly spliced
MUT mRNA, the fibroblast cell line was treated with AMO
and was harvested at 1–25 d. In this experiment, the cor-
rectly spliced mRNA was still at high levels at 10 d, and
trace levels of aberrantly spliced mRNA were obtained. At
15 d, similar amounts of normal and larger fragment were
detected, and no normal transcript was obtained at 25 d
(fig. 4).
In PCCA- and PCCB-mutated fibroblasts, we used one
AMO targeted to the 3′ splice site and the 5′ splice site of
the pseudoexon, respectively, and analysis was performed
72 h after AMO delivery. In PCCA RT-PCR analysis, low
levels of the larger band with the 84-bp insertion were
detected in the control sample, as has been described else-
where.25 In the PCCA-deficient patient, the larger band
was completely absent when fibroblasts were exposed to
20 mM of AMO (fig. 3B). In the PCCB-deficient patient,
the larger band also completely disappeared at both con-
centrations of AMO (fig. 3C).
Restoration of Enzymatic Activity in MUT-, PCCA-,
and PCCB-Mutated Fibroblast Cell Lines
To determine whether the RT-PCR studies correlated with
restoration of activities, we measured incorporation of 14C-
propionate to acid-precipitable material (as determination
of MCM activity) and PCC activity in MUT-mutated and
PCC-deficient cell lines, respectively. PCC and MCM ac-
tivities were rescued in the corresponding patients’ fibro-
blasts 48–72 h after treatment with AMO. In the MUT-
mutated heterozygous patient, dose-dependent activity
was rescued at 48 h (fig. 5). The 14C-propionate incorpo-
ration levels were close to 40% compared with control
levels by use of 10 mM AMO and were close to 100% by
use of 15 mM and 20 mM of AMO. In PCC-deficient cell
lines, maximum activities were obtained 72 h after AMO
delivery, reaching control levels of PCC activity (fig. 6).
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Figure 4. Time course of correctly spliced MUT mRNA stability in fibroblasts treated with AMO. Shown is RT-PCR analysis using primers
to amplify MUT and GAPDH genes before treatment and after treatment for up to 25 d with 10 mM AMO targeted to the 5′ splice site.
Figure 5. Functional correction of MCM activity after AMO treat-
ment. MCM activity was measured by incorporation of [14C] into
trichloroacetic acid–precipitable material in the control cell line
(C) and the MUT-mutated cell line untreated or treated with 10,
15, or 20 mM of AMO targeted to the 5′ cryptic splice site. The
cells were harvested 48 h after transfection. The data show the
meanSD from at least four independent experiments, and control
data were obtained from four independent cell lines.
No effect on MCM or PCC activities was obtained after
AMO treatment in cell lines bearing different mutations
and exhibiting some levels of intronic MUT17 or PCCA
gene insertions.
Restoration of Biotinylated Protein in PCCA-Mutated
Fibroblast Cell Line
In the PCCA-deficient cell line, detection of biotinylated
proteins was performed after treatment with the corre-
sponding AMO. As shown in figure 7, PCCA protein,
which is absent before treatment, is detected at close to
normal levels 72 h after transfection with 20 mM AMO.
The protein is already present 48 h after transfection (data
not shown).
Discussion
In this work, we report, for the first time, the applicability
of antisense therapeutics to the correction of aberrant
splicing in two different organic acidemias (three gene
defects), with recovery of functional protein and activity
within the therapeutic range. The targeted sequences cor-
respond to intronic sequences resembling an exon that
are inserted in the mature mRNA, resulting in a PTC-bear-
ing transcript predictably encoding a nonfunctional pro-
tein. The fact that prevention of the aberrant inclusion of
the pseudoexons by use of AMO results in the recovery
of enzymatic activity confirms that the insertions are the
disease-causing mutations in the patients.
The in silico analysis of the pseudoexon 3′ and 5′ splice
sites predict high scores in each case (fig. 1), thus sug-
gesting that such sequences may be included in the ma-
ture mRNA. This prediction holds true for the PCCA gene
insertion, which is detected with standard RT-PCR con-
ditions at very low levels in control cell lines and at higher
levels in samples from patients with frameshift or non-
sense mutations that result in PTC-bearing transcripts de-
graded by NMD.25 The MUT gene insertion can also be
rescued in control cell lines by use of a specific primer,
suggesting that it may be a normally rare transcript part
of the “background” noise of the splicing process.17 Po-
tential 3′ and 5′ splice sites are highly abundant in intronic
sequences, although they alone are insufficient to dictate
exon recognition.26 The fact that pseudoexon inclusion is
not a frequent event during normal splicing has been at-
tributed to defects in splicing regions, despite their ap-
parently good consensus values, and to the enrichment
in splicing silencers.4 However, in the pseudoexons de-
scribed here, a single point mutation activates the pseu-
doexon, thus pointing to their high resemblance to true
exons. This raises the possibility that these pseudoexons
might be part of a splice-controlling mechanism in which
alternative splicing events can regulate gene expression
by inducing the inclusion of the apparent pseudoexon and
leading to NMD, as described for the tropomyosin gene.27
In the MUT-mutated and PCCB-deficient patients in-
cluded in this study, a point mutation raises slightly the
splicing score of the 5′ splice site of the corresponding
pseudoexon, resulting in its aberrant inclusion in the
mRNA. In the PCCA-deficient patient, the only change
identified in the pseudoexonic region corresponds to an
ArG change in the middle of the pseudoexon. Analysis
with ESE prediction softwares (ESEfinder and Rescue-ESE)
identified loss of an ESE and creation of novel ESE se-
quences, specifically a novel binding site for SRp40 (ESE-
finder). This, in conjunction with the high-score cryptic
3′ and 5′ sites, most likely favors the pathogenic intronic
inclusion. SRp40 knock-down experiments will also help
to clarify the underlying mechanism.
In all three cases, evidence that the pseudoexon inser-
tion is caused by the identified intronic mutations is pro-
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Figure 6. Functional correction of PCC activity after AMO treat-
ment. PCC activity was measured 72 h after transfection with 0,
10, or 20 mM of the corresponding AMO in PCCA- and PCCB-deficient
cell lines. The black bar corresponds to control PCC activity mea-
sured in four independent cell lines. Dark-gray bars show PCC ac-
tivity in PCCA-deficient fibroblasts treated with AMO targeted to
the 3′ cryptic splice site. Light-gray bars show PCC activity in PCCB-
deficient fibroblasts treated with AMO targeted to the 5′ cryptic
splice site. The data show the meanSD from at least three in-
dependent experiments.
Figure 7. Recovery of biotinylated PCCA protein after AMO treat-
ment. Biotinylated proteins were detected in total cellular extract
by avidin-alkaline phospahatase assay in the PCCA-deficient cell
line untreated (lane 1) or 72 h after treatment with the corre-
sponding AMO (lane 2). Lane 3, Hepatoma cellular extract. Shown
are the biotin-containing a-subunits of methylcrotonylCoA car-
boxylase (MCCA) and PCCA.
vided by the results obtained with minigenes. The mutant
constructs resulted in pseudoexon inclusion. In the MUT
wild-type minigene, some amount of transcript with the
insertion is detected, as would be expected given that it
is also detectable in control cell lines. However, for PCCA
and PCCB wild-type minigenes, practically no transcript
with the pseudoexon insertion is detected. In the PCCA-
mutant minigene, only part of the resulting transcripts
corresponds to the insertion. This does not exactly mimic
the results obtained in patients’ fibroblasts, probably be-
cause of the lack of a wide-enough genomic context of
the cloned pseudoexon, as has been described for exon
37 in the NF1 gene.4,28 A cloning-created cryptic exon de-
rived from the vector, as occurs in the PCCB minigene, is
a common occurrence with pSPL3,29 but it is clear that
the PCCB pseudoexon is included with the mutant con-
struction but not with the wild-type one, confirming that
the change leads to pseudoexon insertion.
The splicing correction by AMO was sequence specific,
since control oligomers against another gene had no effect
in each case. No obvious cytotoxicity was observed in the
three cases. The persistence of correctly spliced MUT
mRNA 15 d after termination of AMO delivery suggests
that AMO are quite stable in the cell. In all cases, close to
100% of correctly spliced mRNA was detected after stan-
dard RT-PCR analysis, although, with a specific primer, the
presence of aberrant transcript could be confirmed. This
could be because the aberrant transcript is unstable as a
result of the presence of PTC, and the normally spliced
mRNA is amplified preferentially. In addition, the cor-
rectly spliced mRNA can be translated into significant
amounts of active protein, reaching control levels, as
judged by the detection of biotinylated PCCA protein in
one case and enzymatic assays of all three cell lines.
All these results suggest that the antisense approach may
be clinically promising for organic acidemias.Quantitative
analysis of the restoration of enzymatic activity in a pa-
tient to 30%–40% of the normal level (the minimum value
we obtained for the heterozygous MUT-mutated patient)
is therapeutically significant since heterozygotes are
asymptomatic. Interestingly, in both the heterozygous
and homozygous patients, control activity levels can be
reached with AMO treatment. This suggests that, in the
treated-cell population, the amount of functional protein
synthesized from the normally spliced mRNA is sufficient
to correct the enzymatic defect. Studies in model animals,
not feasible to date, would be highly important for dis-
cussions of the applicability of these therapies to organic
acidemias. To date, treatment of PA and MMA relies on a
protein-restricted diet and administration of carnitine and
antibiotics, although management is sometimes poor, and
long-term complications are common.30 Our results offer
a novel mutation-specific therapeutic approach for these
diseases, which may be applicable to a greater number of
cases than is apparent at the moment, because aberrant
intronic insertions may remain undetected with standard
mutation-detection techniques. In this sense, we have de-
tected only one mutation in several patients with PA
and MMA (laboratory data) who could harbor this type
of mutation that results in PTC transcripts that are de-
graded. Treatment of cell cultures with puromycin to
avoid NMD before RNA analysis may reveal additional
intronic insertions.
Morpholino analogs of oligonucleotides have several
characteristics that render them suitable for therapeutic
applications, such as high binding specificity and stability
and resistance to nucleases and to degradation by RNAseH
when forming hybrids with RNA. The major issues facing
clinical applications concern safe delivery and optimal
dose determination for each tissue involved. Efficient and
nontoxic delivery of AMO to the liver, which would be
the target tissue in these diseases, is one major challenge
to be overcome before the practical use of AMO in patients
with organic acidemia can be envisaged. In Duchenne
muscular dystrophy, antisense oligonucleotides have been
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administered intravenously to patients, achieving splicing
modulation to restore the coding frame for dystrophin.31
The efficacy of antisense therapeutics for splicing correc-
tion must be determined in each disease model and for
each deleterious splicing event, although the results re-
ported to date predict a broad applicability.7,11,12
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